Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign in or Register to read more
7488
Related Questions
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
At what point would you recommend initiating psychotherapy or psychotropic medications to manage mood and anxiety symptoms following a new oncology diagnosis in pediatric patients?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
How do you decide between HSCT and immunosuppressive therapy for treating hepatitis associated aplastic anemia?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?